Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

Blood

Volumn 122, Issue 7, 2013, Pages 1293-1304

  Cramer Morales, Kimberly ^a   Nieborowska Skorska, Margaret ^a   Scheibner, Kara ^b   Padget, Michelle ^b   Irvine, David A ^c   Sliwinski, Tomasz ^a,d   Haas, Kimberly ^e   Lee, Jaewoong ^f   Geng, Huimin ^f   Roy, Darshan ^g   Slupianek, Artur ^a   Rassool, Feyruz V ^b   Wasik, Mariusz A ^g   Childers, Wayne ^e   Copland, Mhairi ^c   Müschen, Markus ^f   Civin, Curt I ^b   Skorski, Tomasz ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF LODZ   (Poland)

^e TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CD34 ANTIGEN; DAUNORUBICIN; HISTONE H2AX; IMATINIB; KI 67 ANTIGEN; PEPTIDE APTAMER; PHENYLALANINE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; RAD51 PROTEIN; RAD52 PROTEIN; RAR PROTEIN; UNCLASSIFIED DRUG; BCR ABL PROTEIN; BCR ABL1 FUSION PROTEIN, HUMAN; BCR-ABL1 FUSION PROTEIN, HUMAN; MESSENGER RNA; PEPTIDE FRAGMENT; TUMOR MARKER;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL EXPANSION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DOUBLE STRANDED DNA BREAK; DRUG TARGETING; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LEUKOCYTOSIS; MICROARRAY ANALYSIS; MOLECULAR MODEL; MOUSE; MUTAGENESIS; NONHUMAN; PANCREAS CARCINOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; QUANTITATIVE ANALYSIS; RECOMBINATION REPAIR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; SPLENOMEGALY; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE; ANIMAL; CANCER STEM CELL; CASE CONTROL STUDY; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; CHEMISTRY; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; DNA DAMAGE; DNA MICROARRAY; DNA REPAIR; DRUG ANTAGONISM; DRUG SCREENING; GENETIC RECOMBINATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE; TUMOR RECURRENCE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; APTAMERS, PEPTIDE; BLOTTING, WESTERN; BRCA1 PROTEIN; BRCA2 PROTEIN; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; EPIGENOMICS; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, SCID; MODELS, MOLECULAR; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE FRAGMENTS; RAD51 RECOMBINASE; RAD52 DNA REPAIR AND RECOMBINATION PROTEIN; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887156264     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-501072     Document Type: Article

References (50)

1. Frame FM, Maitland NJ. Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv Exp Med Biol. 2011; 720:105-118.
2. Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett. 2008; 270(1):1-9.
3. Callén E, Jankovic M, Difilippantonio S, et al. ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. Cell. 2007; 130(1):63-75.
4. Hasham MG, Donghia NM, Coffey E, et al. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. Nat Immunol. 2010;11(9):820-826.
5. Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12(12):801-817.
6. Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47(4):497-510.
7. Karanam K, Kafri R, Loewer A, Lahav G. Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. Mol Cell. 2012;47(2):320-329.
8. Feng Z, Scott SP, Bussen W, et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci USA. 2011; 108(2):686-691.
9. Tarsounas M, Davies D, West SC. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene. 2003;22(8): 1115-1123.
10. Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood. 2011;117(23): 6074-6082.
11. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035): 917-921.
12. Deutsch E, Jarrousse S, Buet D, et al. Downregulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood. 2003;101(11): 4583-4588.
13. Alcalay M, Meani N, Gelmetti V, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest. 2003;112(11): 1751-1761.
14. Viale A, De Franco F, Orleth A, et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature. 2009;457(7225):51-56.
15. Nieborowska-Skorska M, Kopinski PK, Ray R, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 2012; 119(18):4253-4263.
16. Bolton-Gillespie E, Schemionek M, Klein HU, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013;121(20): 4175-4183.
17. Li L, Li M, Sun C, et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell. 2011;20(5):591-605.
18. Scardocci A, Guidi F, D'Alo F, et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer. 2006;95(8):1108-1113.
19. Borghouts C, Kunz C, Groner B. Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci. 2005;11(11): 713-726.
20. Slupianek A, Dasgupta Y, Ren SY, et al. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 2011;118(4):1062-1068.
21. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372(3):774-797.
22. Kagawa W, Kurumizaka H, Ishitani R, et al. Crystal structure of the homologous-pairing domain from the human Rad52 recombinase in the undecameric form. Mol Cell. 2002;10(2): 359-371.
23. Budke B, Logan HL, Kalin JH, et al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 2012;40(15): 7347-7357.
24. Huang F, Mazina OM, Zentner IJ, Cocklin S, Mazin AV. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. J Med Chem. 2012;55(7): 3011-3020.
25. Wolanin K, Magalska A, Kusio-Kobialka M, et al. Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubule-targeting agents. Mol Cancer Ther. 2010;9(5):1328-1338.
26. Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001;8(4): 795-806.
27. Chen G, Yuan SS, Liu W, et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem. 1999;274(18):12748-12752.
28. Kurumizaka H, Aihara H, Kagawa W, Shibata T, Yokoyama S. Human Rad51 amino acid residues required for Rad52 binding. J Mol Biol. 1999; 291(3):537-548.
29. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108(1):319-327.
30. Kagawa W, Kagawa A, Saito K, et al. Identification of a second DNA binding site in the human Rad52 protein. J Biol Chem. 2008; 283(35):24264-24273.
31. Lloyd JA, McGrew DA, Knight KL. Identification of residues important for DNA binding in the fulllength human Rad52 protein. J Mol Biol. 2005; 345(2):239-249.
32. Honda M, Okuno Y, Yoo J, Ha T, Spies M. Tyrosine phosphorylation enhances RAD52-mediated annealing by modulating its DNA binding. EMBO J. 2011;30(16):3368-3382.
33. Chun J, Buechelmaier ES, Powell SN. Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. Mol Cell Biol. 2013;33(2):387-395.
34. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
35. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13): 3657-3660.
36. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20): 5565-5572.
37. Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501-1510.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
39. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3): 193-204.
40. Verga Falzacappa MV, Ronchini C, Reavie LB, Pelicci PG. Regulation of self-renewal in normal and cancer stem cells. FEBS J. 2012;279(19): 3559-3572.
41. Bartkova J, Horejsí Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434(7035):864-870.
42. Sonoda E, Sasaki MS, Buerstedde JM, et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J. 1998;17(2):598-608.
43. Tsuzuki T, Fujii Y, Sakumi K, et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA. 1996; 93(13):6236-6240.
44. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin. 2011;61(1):31-49.
45. Wahlberg E, Karlberg T, Kouznetsova E, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012;30(3):283-288.
46. Ménissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003;22(9): 2255-2263.
47. Liu J, Heyer WD. Who's who in human recombination: BRCA2 and RAD52. Proc Natl Acad Sci USA. 2011;108(2):441-442.
48. Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol. 2004;24(21):9305-9316.
49. Dierov J, Sanchez PV, Burke BA, et al. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia. 2009;23(2):279-286.
50. Seo J, Kim SC, Lee HS, et al. Genome-wide profiles of H2AX and g-H2AX differentiate endogenous and exogenous DNA damage hotspots in human cells. Nucleic Acids Res. 2012; 40(13):5965-5974.